Our staff is here to support the community during these difficult times. We are safely and effectively communicating with clients by phone, email and video conference. Contact Us Today!

Purdue Pharma Opioid Settlement: What You Should Know

In September 2019, Purdue Pharma reached an agreement to settle the large number of pending claims against their company. Purdue and its subsidiaries decided to file for Chapter 11 bankruptcy, which will help restructure the company, remove the company’s founding family and restrict where and how Purdue Pharma can do business moving forward.

Read More

What Role Did Pharmacies Play in the Opioid Epidemic?

Since 2000, the opioid epidemic has claimed the lives of more than 400,000 Americans. Drug company marketing campaigns and the practices of the Drug Enforcement Administration (DEA) are responsible for over 100 related deaths per day.

Read More

When “Sometimes” Is Not An Option

When we use drugs prescribed by doctors, we take for granted that they will help us get over an illness or improve some negative medical condition which we are experiencing. Sometimes though, prescribed medicines we take to make us better have serious negative side effects. You need to know what these are.

Read More

The Risks of Prenatal Opioid Use & Exposure

Prenatal opioid exposure is a growing public health crisis, yet there has been limited data concerning the effects of opioids on developing children. A recent study presented at the Radiological Society of North America (RSNA) found that prenatal exposure to opioids may alter connectivity in the area of the brain that regulates emotions.

Read More

FDA Approves Invokana for Diabetic Kidney Disease and Heart Failure Risks

The FDA has approved Invokana to reduce end-stage kidney disease, decreased kidney function, cardiovascular health and heart failure in adult patients living with Type 2 diabetes and diabetic kidney disease (nephropathy). Invokana is an SGLT2 inhibitor associated with amputation and diabetic ketoacidosis risks.

Read More